<DOC>
	<DOCNO>NCT00846872</DOCNO>
	<brief_summary>The hypothesis GHRP-3 exert beneficial effect endothelial function insulin resistance old men woman via hormonal ( GH , IGF-I , IGFBP-3 , -1 , insulin ) non-hormonal action ( anti-inflammatory ) .</brief_summary>
	<brief_title>Effect Continuous GHRP-3 Infusion GH-IGF-I System , Blood Pressure , Glucose , Insulin Resistance</brief_title>
	<detailed_description>At low dose 0.1 µg/kg/h , GHRP-3 presumably improve endothelial dysfunction , enhance insulin action lower blood pressure via anti-inflammatory effect GHRP-3 high dose 0.5 µg/kg/h GHRP-3 anti-inflammatory effect augment hormonal action increase serum IGF-I primary serum bind protein insulin like growth hormone bind protein - 3 ( IGFBP-3 well -1 ) . Also , detail inter-relationships action GHRP-3 , GH IGF-I serum glucose , blood pressure , lipid level 24h period determine end 14 day placebo two GHRP-3 infusion period . The GHRP-3 administer escalate dos . The Specific Aims study follow : 1 . To determine relative effect 0.1µg/kg/h 0.5µg/kg/h GHRP-3 compare placebo infusion induce physiological secretion GH-IGF-I system continuous sc delivery 14 day healthy old men woman insulin resistance . 2 . To determine relative interrelated effect 0.1 0.5µg/kg/h GHRP-3 infusion placebo various hormonal non hormonal aspect insulin resistance blood pressure ( BP ) , plasma glucose FFA well GH , IGF-I , IGFBP-1 , -3 , insulin endothelin-1 level . 3 . To determine relative effect placebo 2 dos GHRP-3 infusion flow mediate dilation ( FMD ) nitroglycerin-dependent dilation</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>1 . Men postmenopausal woman 5070 year . 2 . Elevated fast plasma glucose range &lt; 125 mg/dL 3 . Waist circumference &gt; 35 inch woman &gt; 40 inch men 1 . Patients take medication may alter carbohydrate metabolism and/or insulin resistance . 2 . Female patient positive pregnancy test . 3 . Previous history hypersensitivity GHRP . 4 . Patients overt liver disease , renal disease and/or congestive heart failure . 5 . Patients anticipated change medication regimen study period . 6 . Current use history use hormone replacement therapy last six month . 7 . Current use history use Ace Inhibitors Angiotensin receptor blocker last six month . 8 . Hemoglobin &lt; 11.6 g/dL woman &lt; 12.9 g/dL men .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>GHRP-3</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Markers inflammation</keyword>
	<keyword>Endothelial Dysfunction</keyword>
	<keyword>Flow Mediated Dilation</keyword>
	<keyword>GH/IGF-1 axis</keyword>
	<keyword>Post menopausal</keyword>
</DOC>